https://sciex.com/content/SCIEX/na/us/en


Discover The Benefits of Knowledge Base Articles

Aug 7, 2017 | Blogs, Technology | 0 comments

Did you know you can access Knowledge Base Articles for trending user questions compiled and answered by SCIEX support experts? Doing so may help to reduce your support calls, not to mention downtime. Instead of waiting for a problem to occur, you can stay on top of it, and be a part of the solution. To give you an idea of trending articles, consider the how this past month saw questions and answers including:

As you will see, many of the new articles are focused on our SCIEX industry-leading software such as SCIEX OS and BioPharmaView. Make sure to visit the Knowledge Base to learn all the tips and trick so that you can get the max out of your software.

What is Premium Access Content?
Now to the business of premium versus non-premium content. Premium Access Content is available to customers who own a mass spectrometer or CE instrument under warranty, or to anyone who has purchased a Software Support Plan. More specifically, the difference between premium and non-premium content is that premium content includes access to advanced workflows.

Knowledge Base Articles versus Community Discussions
The difference between the Knowledge Base Articles and Community Discussions is that Knowledge Base Articles come from the SCIEX support team and are based on common questions. If we see a trend in customer inquiries, the support team will create and post an article to help everyone out. Alternatively, the community is the ideal place to pose a question and get help from your peers. See a question that has yet to be answered?

A 2-fold revolution: MS approaches for the bioanalysis of oligonucleotide therapeutics

In 1998, the US Food and Drug Administration (FDA) approved fomivirsen as the first therapeutic oligonucleotide therapeutic. This approval marked a revolution of mechanism of action discovered decades before finally coming to fruition. Since then, the landscape of chemical modifications of oligonucleotides, conjugations and formulations has evolved tremendously, contributing to improvements in stability, efficacy and safety. Today, more than a dozen antisense oligonucleotides (ASOs) and small interfering RNA (siRNA) drugs are on the market, most of which are designated as orphan drugs for treating rare genetic diseases.

Is “right first time, every time” a pipedream for metabolite identification by LC-MS?

If we lived in an ideal world, it would be possible to unambiguously identify metabolites using a single analytical experiment. This analytical technique would need to be efficient and easily generate the information needed from a routine assay that is also robust, enabling confident decision-making during drug discovery.

Supporting new CRISPR gene editing systems

Prime editing (PE) is a next-generation gene editing technology that utilizes a Cas9 protein fused to a prime editing guide ribonucleic acid (pegRNA) to achieve high CRISPR/Cas9 editing efficiency and precision. However, the length requirement of pegRNAs at 120–250 nucleotides (nt) and their high level of secondary structure formation present analytical challenges for the purity analysis of chemically synthesized pegRNAs during development and quality control (QC).

Posted by

0 Comments

Submit a Comment

Wordpress Social Share Plugin powered by Ultimatelysocial